Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:
  • Enrolling by invitation  
  • « Prev · Page 3

NCT ID: NCT02930265 Enrolling by invitation - Clinical trials for Ischemic Cardiomyopathy

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Start date: September 2016
Phase: N/A
Study type: Interventional

It has been known that liraglutide reduces infarct size, improved left ventricular function, reduce myocardial stunning, and play a protective role in myocardial ischemia-reperfusion injury for patients with acute myocardial infarction. But it is not sure whether liraglutide can benefit patients with ischemic cardiomyopathy. This study aim to explore the effect of Liraglutide in improving cardiac function for patients with ischemic cardiomyopathy.

NCT ID: NCT02440217 Enrolling by invitation - Type 2 Diabetes Clinical Trials

Myocardial Metabolism in Patients With Dilated Cardiomyopathy

Start date: May 2015
Phase: N/A
Study type: Observational

Dilated cardiomyopathy (DCM) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to workload increments. The investigators aimed at verifying whether this pattern is influenced by the presence of abnormal glucose tolerance (AGT).

NCT ID: NCT02413450 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.